Chi Sheng Pharma & Biotech Co (ROCO:4111) Current Deferred Revenue: NT$0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4111 Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
82 GF Score
Price NT$28.70
GF Value NT$33.18
Valuation Modestly Undervalued
View Full Analysis

What is Chi Sheng Pharma & Biotech Co Current Deferred Revenue?

Chi Sheng Pharma & Biotech Co ROCO:4111 +0.17% 82 Current Deferred Revenue is NT$0 Mil as of Jun. 2026. GuruFocus rates ROCO:4111 with a GF Score™ of 82/100 and a GF Value™ of NT$33.18 (Modestly Undervalued).

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Chi Sheng Pharma & Biotech Co's current deferred revenue for the quarter that ended in Jun. 2026 was NT$0 Mil.

Chi Sheng Pharma & Biotech Co Current Deferred Revenue Related Terms

Chi Sheng Pharma & Biotech Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Chi Sheng Pharma & Biotech Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chi Sheng Pharma & Biotech Co Current Deferred Revenue Chart

Chi Sheng Pharma & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chi Sheng Pharma & Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4111
82GF Score
Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0 Mil mean?
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a Current Deferred Revenue of NT$0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Chi Sheng Pharma & Biotech Co and its competitors.
Is Chi Sheng Pharma & Biotech Co's Current Deferred Revenue too high?
Chi Sheng Pharma & Biotech Co's current Current Deferred Revenue is NT$0 Mil. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's Current Deferred Revenue compare to ISRG and BDX?
Chi Sheng Pharma & Biotech Co's Current Deferred Revenue of NT$0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. Chi Sheng Pharma & Biotech Co's current Current Deferred Revenue is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.18, compared to a current price of NT$28.70 — trading 13.5% below its estimated fair value. The current Current Deferred Revenue is NT$0 Mil. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 82/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current Current Deferred Revenue is NT$0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?

Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued. The current stock price of NT$28.70 is trading 13.5% below its estimated GF Value™ of NT$33.18. GuruFocus considers Chi Sheng Pharma & Biotech Co to be Modestly Undervalued.

Key valuation signals for ROCO:4111:

  • Current Deferred Revenue: NT$0 Mil
  • GF Value™: NT$33.18 vs. price of NT$28.70 (13.5% below fair value)
  • GF Score™: 82/100

No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chi Sheng Pharma & Biotech Co Business Description

Address No. 3, Shijian Road, Hsin Chu Industrial Park, Hsinchu County, Hukou, TWN, 30316
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
82GF Score

Get the complete analysis for ROCO:4111

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.70
Price
NT$33.18
GF Value